TABLE 3.
Afghanistan | Bangladesh | Bhutan | India | Maldives | Myanmar | Nepal | Pakistan | Sri Lanka | |
---|---|---|---|---|---|---|---|---|---|
No of articles on ISS indexed in PubMed or Scopus | None | 5 | 0 | >100 | None | 0 | 3 | 10 | 8 |
Abstracts if no full texts | None | NA | None | NA | None | 2 | NA | NA | NA |
Reported incidence/prevalence of WS per 1000 | None | None | None | Age specific prevalence: 0.0628/1000 | None | None | None | None | |
Proportion with** | |||||||||
Structural etiology | None | None | None | 82% (CI: 75%‐89%) | None | None | None | 75% (CI: 57%‐89%) | 68% (CI: 57%‐78%) |
Acquired structural insult | None | None | None | 71% (CI: 61%‐80%) | None | None | None | 64% (CI: 55%‐73%) | 62% (51%‐73%) |
Described etiologies of WS | None |
HIE/Perinatal asphyxia: 58% TORCH: 3.22% Brain malformation: 3.22%, Neonatal Hyperbilirubinemia: 3.22%, Neonatal sepsis: 3.2% Unknown: 6.5%* |
None |
Perinatal asphyxia/HIE (34.6%) Hypoglycemic brain injury (HBI) 16.7% Combined HIE and HBI (9%) Congenital brain malformations (3%) Other structural (10.7%) Infections (0.7%) Metabolic (0.7%) Proven genetic (7.2%) Not known/incompletely investigated (17.1%)^ |
None |
|
|
|
Known‐ 71% Unknown −18% Incompletely investigated −11% |
Average age of onset (months) | NR | 5** | NR | NR | NR | 5.5# | 6### | 4‐6# | 5** |
Average lead time to diagnosis/treatment (months) | NR | 7.5** | NR | 4.4** | NR | NR | NR | 6 | 1.4** |
Ratio of male in comparison to female | NR | 2.1** | NR | 2.6** | NR | 1.44# | NR | NR | 1.36** |